{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:55:13Z","timestamp":1793163313827,"version":"4.5.0"},"reference-count":17,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,2,26]],"date-time":"2010-02-26T00:00:00Z","timestamp":1267142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Incidence of psoriasis vulgaris in Asians is estimated at 0.05\u20130.3%. Studies in North America and Europe demonstrated that adalimumab, a fully human, recombinant, immunoglobulin G<jats:sub>1<\/jats:sub> monoclonal antibody, was efficacious and well\u2010tolerated in patients with chronic plaque psoriasis. This 24\u2010week, placebo\u2010controlled study evaluated the efficacy and safety of three different dosing regimens of adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis (<jats:italic>n<\/jats:italic>\u2003=\u2003169). Patients were randomized to receive adalimumab 40\u2003mg every other week (eow), adalimumab 80\u2010mg loading dose at week 0 followed by adalimumab 40\u2003mg eow starting at week 2, adalimumab 80\u2003mg eow, or placebo eow given as s.c. injections. The primary efficacy endpoint was the percentage of patients achieving a 75% or greater improvement in Psoriasis Area and Severity Index (PASI 75) score at week 16. At week 16, PASI 75 response rates were significantly greater for all three adalimumab groups (40\u2003mg\u2003eow: 57.9%, <jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.001; 40\u2003mg eow plus loading dose: 62.8%, <jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.001; 80\u2003mg eow: 81.0%, <jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.001) versus placebo (4.3%). As early as week 4, the 40\u2010mg eow plus loading dose and 80\u2010mg eow groups achieved significantly greater PASI 75 response rates compared with placebo. Injection\u2010site reactions and hepatic events occurred in greater percentages of adalimumab\u2010treated patients compared with placebo. Adalimumab therapy demonstrated efficacy and safety at all three dosage regimens. Rapid response rate in patients receiving 40\u2003mg eow plus loading dose supports using an 80\u2010mg loading dose in the treatment of psoriasis.<\/jats:p>","DOI":"10.1111\/j.1346-8138.2009.00748.x","type":"journal-article","created":{"date-parts":[[2010,2,26]],"date-time":"2010-02-26T06:41:46Z","timestamp":1267166506000},"page":"299-310","source":"Crossref","is-referenced-by-count":167,"title":["Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II\/III randomized controlled study"],"prefix":"10.1111","volume":"37","author":[{"given":"Akihiko","family":"ASAHINA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemi","family":"NAKAGAWA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"ETOH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamitaro","family":"OHTSUKI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"THE ADALIMUMAB M04\u2010688 STUDY GROUP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,3,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503023320907"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02552.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(84)80314-X"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(02)00142-1"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.117047"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)80148-4"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(05)70306-5"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-29018-6_3"},{"key":"e_1_2_6_11_2","volume-title":"HUMIRA\u00ae [Prescribing Information]","year":"2009"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.027"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-008-0045-0"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01667.x"},{"key":"e_1_2_6_17_2","first-page":"280","article-title":"The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient\u2010membership survey","volume":"137","author":"Krueger G","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1346-8138.2009.00748.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1346-8138.2009.00748.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T10:10:52Z","timestamp":1698919852000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1346-8138.2009.00748.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,25]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1111\/j.1346-8138.2009.00748.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1346-8138.2009.00748.x","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,25]]}}}